Binding site of loperamide: Automated docking of loperamide in human μ- and δ-opioid receptors

Chemical Biology and Drug Design

Volumn 71, Issue 4, 2008, Pages 328-335

  Di Bosco, Antonio Mazzella ^a   Grieco, Paolo ^a   Diurno, Maria Vittoria ^a   Campiglia, Pietro ^b   Novellino, Ettore ^a   Mazzoni, Orazio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

AutoDock; Automatic docking; Binding site of loperamide; Human and opioid receptors

Indexed keywords

DELTA OPIATE RECEPTOR; LOPERAMIDE; MU OPIATE RECEPTOR; PHENYL GROUP;

ARTICLE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; LIPOPHILICITY; MOLECULAR MODEL; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; BINDING SITES; COMPUTER SIMULATION; HUMANS; LOPERAMIDE; MODELS, MOLECULAR; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

EID: 40449114230     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00637.x     Document Type: Article

References (45)

1. Estafanousm F.G. 1991) ed. Opioids in Anesthesia II. Butterworth- Heinemann, Stoneham, MA.
2. Foley K.M. 1993) Opioid-Analgesics in Clinical Pain Management. In : Herz A. editor. Handbook of Experimental Pharmacology. vol. 104; Opioids II. Springer-Verlag. Berlin. p. 697 737.
3. Lenz G.R., Evans S.M., Walters D.E., Hopfinger A.J., Hammond D.L. 1986) eds. Opiates. Academic Press, Orlando, FL.
4. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. (1976) The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197 : 517 532.
5. Tempel A., Zukin R.S. (1987) Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc Natl Acad Sci USA 84 : 4308 4312.
6. Wang J.B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A., Uhl G.R. (1994) Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 338 : 217 222.
7. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., Reisine T. (1994) Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 45 : 330 334.
8. Knapp R.J., Malatynska E., Fang L., Li X., Babin E., Nguyen M., Santoro G., Varga E.V., Hruby V.J., Roeske W.R., Yamamura H.I. (1994) Identification of a human delta opioid receptor: cloning and expression. Life Sci 54 : PL463-9.
9. Surratt C.K., Johnson P.S., Moriwaki A., Seidleck B.K., Blaschak C.J., Wang J.B., Uhl G.R. (1994 mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem 269 : 20548 20553.
10. Hjorth S. A., Thirstrup K., Grandy D.K., Schwartz T.W. (1995) Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine. Mol Pharmacol 47 : 1089 1094.
11. Befort K., Tabbara L., Bausch S., Chavkin C., Evans C., Kieffer B. (1996) The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol Pharmacol 49 : 216 223.
12. Befort K., Tabbara L., Kling D., Maigret B., Kieffer B. L. (1996) Role of aromatic transmembrane residues of the delta-opioid receptor in ligand recognition. J Biol Chem 271 : 10161 10168.
13. Valiquette M., Vu H. K., Yue S. Y., Wahlestedt C., Walker P. Involvement of Trp-284, Val-296, Val-297 of the Human delta-Opioid Receptor in Binding of delta-Selective Ligands. J Biol Chem. 1996, 271, 18789 18796.
14. Claude P.A., Wotta D.R., Zhang X.H., Prather P.L., McGinn T.M., Erickson L.J., Loh H.H., Law P.Y. (1996) Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc Natl Acad Sci USA 93 : 5715 5719.
15. Strader C.D., Fong T.M., Tota M.R., Underwood D., Dixon R.A. (1994) Structure and function of G protein-coupled receptors. Annu Rev Biochem 63 : 101 132.
16. Heykants J., Michiels M., Knaeps A., Brugmans J. (1974) Loperamide (R 18553), a novel type of antidiarrheal agent. Arzneimittelforschung 24 : 1649 1653.
17. Doser K., Meyer B., Nitsche V., Binkert-Graber P. (1995) Bioequivalence evaluation of two different oral formulations of loperamide (Diarex lactab vs Imodium capsules). Int J Clin Pharmacol Ther 33 : 431 436.
18. Weintraub H.S., Killinger J. M., Keykants J., Kanzler M., Jaffe J. H. (1977) Studies on the elimination rate of loperamide in man after administration of increasing oral doses of Imodium. Curr Ther Res 21 : 867 876.
19. McCowat L.A., Cutting W.A., Steinke D., McDonald T.M. (1997) Treating diarrhea: children deserve special attention. Br Med J 315 : 1378 1379.
20. Bhutta T.I., Tahir K.I. (1990) Loperamide poisoning in children. Lancet 335 : 363.
21. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L.V. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97 : 2517 2524.
22. Diurno M.V., Izzo A.A., Mazzoni O., Bolognese A., Capasso F. (1996) Antidiarrhoeal activity of new thiazolidinones related to loperamide. J Pharm Pharmacol 48 : 760 762.
23. Diurno M.V., Mazzoni O., Capasso F., Izzo A.A., Bolognese A. (1997) Synthesis and pharmacological activity of 2-(substituted phenyl)-3-[2 or 3-[(4-substituted phenyl-4-hydroxy)piperidino]ethyl or propyl]-1,3-thiazolidin- 4-ones. Farmaco 52 : 237 241.
24. Mazzoni O., Mazzella di Bosco A., Grieco P., Novellino E., Bertamino A., Borrelli F., Capasso R., Diurno M.V. (2006) Synthesis and pharmacological activity of 2-(substituted)-3-{2-[(4-phenyl-4-cyano)piperidino]ethyl}-1, 3-thiazolidin-4-ones. Chem Biol Drug Des 67 : 432 436.
25. DeHaven-Hudkins D.L., Burgos L.C., Cassel J.A., Daubert J.D., DeHaven R.N., Mansson E., Nagasaka H., Yu G., Yaksh T. (1999) Loperamide (ADL2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 289 : 494 502.
26. Cambridge Structural Database System Users Manual (1994 Cambridge Crystallographic Data Centre, Cambridge, UK.
27. Surratt C.K., Johnson P.S., Moriwaki A., Seidleck B.K., Blaschak C.J., Wang J.B., Uhl G.R. (1994) -mu Opiate receptor: Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. Biol Chem 269 : 20548 20553.
28. Mansour A., Taylor L.P., Fine J.L., Thompson R.C., Hoversten M.T., Mosberg H.I., Watson S.J., Akil H. (1997) Key residues defining the mu-opioid receptor binding pocket: a site directed mutagenesis study. J Neurochem 68 : 344 353.
29. Li J.G., Chen C., Yin J., Rice K., Zhang Y., Matecka D., de Riel J.K., Desjarlais R.L., Liu-Chen L.Y. (1999) ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone. Life Sci 65 : 175 185.
30. Chen C., Yin J., Riel J. K., Desjarlais R.L., Raveglia L.F., Zhu J., Liu-Chen L.Y. (1996) Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor. J Biol Chem 271 : 21422 21429.
31. Goodsell D.S., Olson A.J. (1990) Automated Docking of Substrates to Proteins by Simulated Annealing. Proteins: Structure, Function, and Genetics 8 : 195 202.
32. Morris G.M., Goodsell D.S., Huey R., Olson A.J. (1996) Distributed Automated Docking of Flexible Ligands to Proteins: Parallel Applications of AutoDock 2.4. J Computer-Aided Mol Des 10 : 293 304.
33. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. (1998) Automated Docking Using Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comp. Chem. 19 : 1639 1662.
34. McFadyen I.J., Sobczyk-Kojiro K., Schaefer M.J., Ho J.C., Omnaas J.R., Mosberg H.I., Traynor J.R. (2000) Tetrapeptide derivatives of [D-Pen(2), D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor. Pharmacol. Exp. Ther. 295 : 960 966.
35. Mosberg H.I. (1999) Complementarity of delta opioid ligand pharmacophore and receptor models. Biopolymers 51, 426-439. c) McFadyen I.J., Ho J.C., Mosberg H.I., Traynor J.R. (2000) Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation. J Pept Res 55 : 255 261.
36. Wang C., McFadyen I.J., Traynor J.R., Mosberg H.I. (1998) Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models. Bioorg Med Chem Lett 8 : 2685 2688.
37. Dauber-Osguthorpe P., Roberts V.A., Osguthorpe D.J., Wolff J., Genest M., Hagler A.T. (1988) Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins 4 : 31 47.
38. Allinger N.L., Yuh Y.H., Lii J.H. (1989) Molecular mechanics. The MM3 force field for hydrocarbons. J Am Chem Soc 111 : 8551 8566.
39. Gasteiger J., Marsili M. (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 36 : 3219 3228.
40. Solis F.J., Wets R.J. B. (1981) Minimization by random search techniques. Math. Oper. Res. 6 : 19 30.
41. McConkey B. J., Sobolev V., Edelman M. (2002) The performance of current methods in ligand-protein docking. Curr Sci 83 : 845 856.
42. Wang R.X., Lu Y.P., Wang S.M. (2003) Comparative evaluation of 11 scoring functions for molecular docking J. Med Chem 46 : 2287 2303.
43. Gohlke H., Hendlich M., Klebe G. (2000) Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol 295 : 337 356.
44. Erickson J.A., Jalaie M., Robertson D.H., Lewis R.A., Vieth M. (2004) Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J Med Chem 47 : 45 55.
45. Nissink J.W.M., Murray C., Hartshorn M., Verdonk M.L., Cole J.C., Taylor R. (2002) A new test set for validating predictions of protein-ligand interaction. Proteins: Struct Funct Genet 49 : 457 471.